BA

Bhosle Avinash

Active Director Director DIN 10188488
DIN 10188488 First appointment Jun 2023
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2023
Shareholding value •••• Premium profile

About Bhosle Avinash

Data last updated:

Bhosle Avinash is a Director at Neugenix Pharma Private Limited (since 2023). Neugenix Pharma Private Limited reported revenue of ₹2.9 Lakh (FY 2025).

DIN 10188488
Primary Designation Director
First Appointment 02 Jun 2023
Oldest Company Age 3 yrs
Largest company Neugenix Pharma Private Limited · ₹2.9 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Neugenix Pharma Private Limited U86201KA2023PTC174461
Director02 Jun 20232023₹2.9 Lakh (FY 2025)Active

Board colleagues of Bhosle Avinash

NameDINCompanyDesignation
Vaibhav Bhanudasrao Bhosle10188487Neugenix Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Neugenix Pharma Private Limited
Premium access

Shareholding and investment profile for Bhosle Avinash

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bhosle Avinash

Bhosle Avinash currently holds 1 directorship: Neugenix Pharma Private Limited (Director, since 02 Jun 2023, revenue ₹2.9 Lakh (FY 2025)).

Bhosle Avinash was first appointed on 02 Jun 2023 as Director at Neugenix Pharma Private Limited.

The current boards of Bhosle Avinash's companies include Vaibhav Bhanudasrao Bhosle (Neugenix Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available